Ashvattha Therapeutics Announces Appointment of Dr. Sakura Minami as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations
October 09, 2023 08:30 ET
|
Ashvattha Therapeutics
REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...
In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning to GSK’s Benlysta and AstraZeneca’s Saphnelo for the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus, According to Spherix Global In
October 04, 2023 03:00 ET
|
Spherix Global Insights
Exton, Pennsylvania, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the...
Brusco Vision Unveils Latest Insights on LASIK Safety and Future Procedures
October 03, 2023 19:22 ET
|
Brusco Vision
Falls Church, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Falls Church, Virginia - Renowned ophthalmology clinic, Brusco Vision, takes a transformative step forward with the release of their latest...
Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights
October 03, 2023 13:57 ET
|
Spherix Global Insights
Exton, Pennsylvania, Oct. 03, 2023 (GLOBE NEWSWIRE) -- US rheumatologists (n=204) report nearly two-thirds of their psoriatic arthritis (PsA) patients are undergoing treatment with advanced systemic...
Youtech Helps Local Phoenix Businesses & Private Equity Groups Revamp Their PortCo Websites
October 02, 2023 10:35 ET
|
Youtech
Youtech announces the successful completion of five website projects that have helped private equity groups.
Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer
October 02, 2023 08:00 ET
|
Solid Biosciences Inc.
- Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid’s focus on both...
Novartis completes divestment of ‘front of eye’ ophthalmology assets
September 29, 2023 10:00 ET
|
Novartis Pharma AG
Divestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapiesNovartis advances strategy of focused portfolio and prioritized therapeutic...
Sharps Technology Issues Letter to Shareholders Covering the Announced Asset Purchase Agreement to Acquire InjectEZ Prefillable Syringe Manufacturing Facility and the Associated $400 Million 10-Year Purchase Agreement with Nephron Pharmaceuticals
September 28, 2023 10:52 ET
|
Sharps Technology Inc
Sharps Technology Issues Letter to Shareholders Covering the Announced Asset Purchase Agreement to Acquire InjectEZ Prefillable Syringe Manufacturing Facil
Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy
September 27, 2023 08:30 ET
|
Kriya Therapeutics, Inc.
– Everads' next generation suprachoroidal delivery technology enables targeted drug delivery to the retina, which Kriya intends to use for multiple ophthalmology gene therapy product candidates – ...
Oligonucleotide API Market revenue to surpass USD 5 Billion by 2035, says Research Nester
September 27, 2023 06:07 ET
|
Research Nester
New York, Sept. 27, 2023 (GLOBE NEWSWIRE) -- The global oligonucleotide API market size is projected to expand at ~ 10% CAGR between 2023 and 2035. The market is expected to garner a revenue of USD...